BACKGROUND: Although dual antiplatelet therapy (DAPT) with @entity1397 and @entity117 is a widely accepted strategy in @entity1 undergoing transcatheter aortic valve replacement (TAVR), this approach is not evidence based. We therefore sought to systematically review the current evidence for this practice in terms of 30-day outcome looking at @entity64 , MI, @entity548 , and @entity204 . METHODS: Relevant studies were identified through electronic literature search. Studies involving @entity302 ( @entity302 ) and DAPT in @entity1 undergoing TAVR were included. Study specific risk ratios were calculated and combined using random-effects model meta-analysis. RESULTS: Analysis of data from 410 @entity1 , @entity64 occurred in seven (3.16%) of @entity302 and six (3.17%) of DAPT RR=1.03 (95% CI, 0.36-2.96, P=0.96). In analysis of 530 @entity1 , MI occurred in three (1.07%) of @entity302 and one (0.40%) of DAPT RR=1.97 (95% CI, 0.29-13.29, P=0.49), significant @entity548 (major, life threatening and @entity548 requiring transfusion) occurred in 20 (7.11%) of @entity302 and 43 (17.27%) of DAPT RR=0.41 (95% CI, 0.25-0.69, P=0.0006). Number needed to harm for major or life threatening @entity548 was 10. @entity204 occurred in 15 (6.78%) of @entity302 and 15 (7.94%) of @entity39629 (RR 0.91; 95% CI 0.46-1.79, P=0.78). CONCLUSION: Our meta-analysis suggests that at 30 days following TAVR there is no difference between post-procedural @entity302 versus DAPT for the risk of @entity64 or MI and DAPT may have a higher @entity548 risk. Adequately powered RCTs are warranted to clarify the optimal antiplatelet treatment strategy following TAVR.

Dual Versus Single Antiplatelet Therapy in XXXX Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-analysis.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity39629 :: ('MESH:C028145|MESH:C048518', 'Chemical') :: ['DAPT'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity1397 :: ('MESH:C055162', 'Chemical') :: ['clopidogrel'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity302 :: ('MESH:D004827', 'Disease') :: ['SAPT', 'single antiplatelet therapy'] @entity204 :: ('MESH:D003643', 'Disease') :: ['Death', 'death']
@entity1 :: (9606,Species) :: ['Patients']
